Table 1.
Subject characteristics.
| Total (n = 41) | |
|---|---|
| Mean ± SD (range) or n (%) | |
| Age (year) | 60.2 ± 6.7 (50 – 79) |
| Female (n) | 11 (26.8) |
| African (n) | 4 (9.8) |
| Asian (n) | 2 (4.9) |
| Caucasian (n) | 35 (85.4) |
| Schizophrenia (n) | 33 (80.5) |
| Schizoaffective (n) | 8 (19.5) |
| Age of onset (year-old) | 25.1 ± 9.7 (7 – 48) |
| Duration of illness (year) | 34.3 ± 10.6 (8 – 55) |
| Number of episode (n) | 5.7 ± 4.8 (1 – 20) |
| Number of hospitalization (n) | 5.9 ± 5.4 (0 – 20) |
| Year of antipsychotic exposure (year) | 30.0 ± 11.7 (4 – 55) |
| PANSS total score | 60.2 ± 13.5 (30 – 82) |
| Positive subscale score | 12.8 ± 3.9 (7 – 20) |
| Negative subscale score | 17.9 ± 5 (7 – 28) |
| General psychopathology subscale score | 29.5 ± 6.8 (16 – 43) |
| PANSS factor scores | |
| Positive | 11.24 ± 3.22 (5 – 17) |
| Negative | 22.83 ± 6.70 (10 – 36) |
| Depression | 8.02 ± 2.88 (5 – 15) |
| Disorganized | 7.24 ± 2.44 (3 – 13) |
| Excited/Activation | 6.37 ± 1.67 (5 – 12) |
| Amotivation Factor | 7.88 ± 2.68 (3 – 13) |
| Diminished Expression Factor | 9.51 ± 3.20 (4 – 16) |
| OLZ (n) | 24 (58.5) |
| Daily dose (mg) | 20.6 ± 6.7 (10 – 35) |
| RIS (n) | 17 (41.5) |
| Daily dose (mg) | 4.3 ± 2.5 (2 – 12) |
| CPZ equivalent dose (mg) | 419.5 ± 186.4 (200 – 1200) |
| D2/3R occupancy (%) | 70.4 ± 11.9 (40.6 – 91.2) |
|
| |
| (n=36) | |
| RBANS Total Scores | 76.53 ± 11.64 (52 – 99) |
Abbreviations: PANSS, Positive and Negative Syndrome Scale; OLZ, Olanzapine; RIS, Risperidone; CPZ, Chlorpromazine; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status.